Redhill Biopharma Ltd ADR RDHL
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if RDHL is a good fit for your portfolio.
News
-
RedHill Announces New USPTO Patent Covering Talicia® Through 2034
-
RedHill's Opaganib Selected for Evaluation by BARDA and NIH Countermeasures Programs
-
RedHill's Opaganib Protects Against Radiation-Induced Lung Inflammation and Fibrosis - New Publication
-
RedHill Biopharma Announces Closing of $8 Million Registered Direct Offering
-
RedHill Biopharma Announces $8 Million Registered Direct Offering
-
RedHill Announces New USPTO Patent Grant for Talicia® for H. pylori Treatment Through 2042
-
Thinking about buying stock in Kura Oncology, UiPath, C3.ai, Crowdstrike, or RedHill Biopharma?
-
RedHill Biopharma shares jump as Ebola treatment shows promise
Trading Information
- Previous Close Price
- $0.51
- Day Range
- $0.50–0.55
- 52-Week Range
- $0.26–4.92
- Bid/Ask
- $0.52 / $0.53
- Market Cap
- $15.74 Mil
- Volume/Avg
- 501,085 / 712,344
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 0.04
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults, Talicia for the treatment of Helicobacter pylori infection in adults, and Aemcolo for the treatment of travelers' diarrhea in adults. Its key clinical late-stage development programs include RHB-104 for Crohn's disease; RHB-204, for pulmonary nontuberculous mycobacteria infections; RHB-102 (Bekinda) with positive results from a first Phase 3 study for acute gastroenteritis and gastritis; Opaganib (Yeliva); RHB-106, an encapsulated bowel preparation and RHB-107, a Phase 2-stage serine protease inhibitor targeting cancer and inflammatory gastrointestinal diseases.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Small Growth
- Total Number of Employees
- 113
- Website
- https://www.redhillbio.com
Valuation
Metric
|
RDHL
|
---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.60 |
Price/Sales | 0.04 |
Price/Cash Flow | — |
Price/Earnings
RDHL
Financial Strength
Metric
|
RDHL
|
---|---|
Quick Ratio | 0.46 |
Current Ratio | 0.96 |
Interest Coverage | 0.56 |
Quick Ratio
RDHL
Profitability
Metric
|
RDHL
|
---|---|
Return on Assets (Normalized) | 1.17% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | 15.94% |
Return on Assets
RDHL
Drug Manufacturers - Specialty & Generic Industry Comparables
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
---|---|---|---|---|---|
ZTS
| Zoetis Inc Class A | Gvxrzlnfhh | Clv | $77.5 Bil | |
MKKGY
| Merck KGaA ADR | Yrwtpmllg | Xbzjlz | $76.9 Bil | |
HLN
| Haleon PLC ADR | Ghlmxgm | Tnl | $38.4 Bil | |
TEVA
| Teva Pharmaceutical Industries Ltd ADR | Ggrslbh | Gsdt | $15.9 Bil | |
VTRS
| Viatris Inc | Nbxnwzpy | Hycw | $14.2 Bil | |
RDY
| Dr Reddy's Laboratories Ltd ADR | Szqgyrbmj | Gdlr | $12.3 Bil | |
CTLT
| Catalent Inc | Wvzjxlr | Snhpsc | $10.2 Bil | |
PRGO
| Perrigo Co PLC | Ntttykb | Hvxrt | $4.4 Bil | |
CURLF
| Curaleaf Holdings Inc | Vnlhhkz | Frrbh | $3.9 Bil | |
PBH
| Prestige Consumer Healthcare Inc | Tzgxhzz | Brcswt | $3.6 Bil |